Elmedical News
1 article
growth-positive
Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study - PubMed
The article discusses the efficacy and safety of a new device called Unithermia, developed by Elmedical Ltd, for intravesical thermochemotherapy in non-grade 3 non-muscle-invasive bladder cancer (NMIBC) patients who have failed Bacillus Calmette-Guerin (BCG) treatment. The study shows that Unithermia has an interesting activity and safety profile in this selected subgroup of NMIBC patients, suggesting its potential as a second-line therapy. The article provides details of the study design, patient eligibility, treatment outcomes, and toxicity levels. The key theme of the article is the evaluation of Unithermia as a potential treatment option for non-grade 3 NMIBC patients who have failed BCG. The key issues discussed in the article are related to customers, as the study evaluates the impact of Unithermia on patient outcomes.
Customers